Rodos Biotarget offers TargoSphere® as a “toolbox”: Specific additives and/or components of the nanocarriers can be tailored to suit the respective therapeutic objective. Most importantly, the targeting ligands located on the nanocarrier’s surface permit specific uptake of the active ingredient intended for the target cell.
The TargoSphere® can carry high concentrations of compounds spanning a broad range of sizes and structures of classical small molecule drugs to biomolecules, such as proteins, peptides, and nucleic acids.
Rodos Biotarget’s most advanced TargoSphere® (TS) variants are CLR-TS that exclusively target all antigen-presenting cells and HEP-TS, which exclusively target hepatocytes. These variants are available for collaborative developments. Additionally, Rodos Biotarget is expanding its platform by testing various molecules, some of which are proprietary, as distinctive targeting ligands. These ligands include antibodies, antibody fragments, peptides, carbohydrates, and more.
TargoSphere® nanocarriers can target immune cells, liver cells, cancer cells, and other cell species, thereby enabling the targeted and more effective treatment of immune-mediated, liver-related, neurodegenerative, and oncologic diseases, as well as infectious viral, parasitic and bacterial infections.
The manifold combinations available in the design and their potential medical applications reflect a potent technology platform offering clear and critically important benefits for pharma partners, physicians, and patients.
This TargoSphere® variant is equipped with a carbohydrate ligand that specifically targets and binds to members of the C-type lectin receptor family expressed on the surface of professional antigen-presenting cells (APCs). These immune cells are critical to specifically recognizing pathogens, distinguishing between healthy and malignant cells, and maintaining immunotolerance.
APCs process protein components of ingested pathogens, cancer cells, or “self” molecules. Defined peptides are then presented to T cells. In health, this results in pathogen- or tumor-specific immune responses or the induction of immunotolerance. Therefore, employing the CLR-TargoSpheres® for delivering active agents selectively and efficiently to APCs presents multiple innovative options for therapy and vaccination. The field of cancer immunotherapy (immune-oncology) is expected to benefit from applying CLR-TS delivery to the APCs to mobilize the immune system against malignant diseases.
The TargoSphere® variant HEP-TS is equipped with a proprietary ligand that specifically targets hepatocytes. Because the liver is a central “altruistic” organ, hepatocytes play a key role in overall homeostasis. Against this background, metabolic liver diseases – such as the metabolic syndrome – have wide-ranging effects on the entire organism. For example, non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of obesity and the metabolic syndrome. Globally, NAFLD is emerging as the leading cause of liver cirrhosis and liver transplantation. To specifically address hepatocytes with suitable therapeutics thus promises to avert the progression of NAFLD which leads to life-threatening and costly complications.
Additionally, specific delivery of antivirals to liver parenchymal cells infected with hepatitis virus can optimize therapeutic treatment and prevent toxic systemic side-effects. For the same reasons, autoimmune hepatitis can safely be treated by targeting the affected hepatocytes directly.
Rodos Biotarget produces GMP-grade targeting ligands and TargoSphere® nanocarriers in industrial quantities in GMP-certified facilities.